Astellas Loses Overactive Bladder Drug Patent On Appeal
European appellate officials have revoked an Astellas patent for an overactive bladder treatment, ruling that using a modified-release tablet to reduce the effect of food on drug intake was obvious to...To view the full article, register now.
Already a subscriber? Click here to view full article